Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.52 |
| ▸ | GRM1 | Q13255 | 6/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3349176 | 1.00 | MEN1 (0.55) | MEN1KMT2APOLBGAATGFBR1 | |
| SCHEMBL3348988 | 0.93 | MEN1 (0.51) | MEN1KMT2APOLBGAATGFBR1 | |
| SCHEMBL3348999 | 0.93 | MEN1 (0.51) | MEN1KMT2APOLBGAATGFBR1 | |
| SCHEMBL3352208 | 0.92 | MEN1 (0.53) | MEN1KMT2APOLBGAATGFBR1 | |
| SCHEMBL3349182 | 0.92 | MEN1 (0.55) | MEN1KMT2APOLBGAATGFBR1 | |
| SCHEMBL3352218 | 0.92 | MEN1 (0.53) | MEN1KMT2APOLBGAATGFBR1 | |
| SCHEMBL13166309 | 0.92 | MEN1 (0.55) | MEN1KMT2APOLBGAATGFBR1 | |
| SCHEMBL3351679 | 0.91 | MEN1 (0.58) | MEN1KMT2APOLBGAATGFBR1 | |
| SCHEMBL3351673 | 0.91 | MEN1 (0.58) | MEN1KMT2APOLBGAATGFBR1 | |
| SCHEMBL3355083 | 0.90 | STAT3 (0.47) | MEN1KMT2APOLBGAATGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803945-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-09-28 | — | — | US | claimed |
| EP-1753512-B1 | TETRAHYDROPYRIDOTHIOPHENES | NYCOMED GMBH (DE) | 2008-07-09 | — | — | EP | claimed |
| US-7803945-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-09-28 | — | — | US | disclosed |
| US-7803945-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-09-28 | — | — | US | disclosed |
| US-7803945-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-09-28 | — | — | US | disclosed |
| US-7723523-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7723523-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7723523-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-25 | — | — | US | disclosed |
| US-20090270378-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | NYCOMED GMBH (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270378-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | NYCOMED GMBH (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270378-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | NYCOMED GMBH (DE) | 2009-10-29 | — | — | US | disclosed |
| EP-1753512-B1 | TETRAHYDROPYRIDOTHIOPHENES | NYCOMED GMBH (DE) | 2008-07-09 | — | — | EP | disclosed |
| US-20070244112-A1 | Novel tetrahydropyridothiophenes | ALTANA PHARMA AG (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244112-A1 | Novel tetrahydropyridothiophenes | ALTANA PHARMA AG (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244112-A1 | Novel tetrahydropyridothiophenes | ALTANA PHARMA AG (DE) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270378-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | BAX, BCL2, CCAR2 | MEN1 4646/4885KMT2A 2220/4885POLB 2460/4885 |
| US-20070244112-A1 | Novel tetrahydropyridothiophenes | BAX, BCL2, BAD | MEN1 4610/4885KMT2A 2358/4885POLB 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.